(MENAFN- PRovoke) COPENHAGEN - Novo Nordisk has named US pharmaceutical executive Greg Miley senior VP of corporate affairs, expanding its leadership team at a time when the company faces renewed scrutiny over US drug pricing policy.

Miley announced the move on LinkedIn, writing that he will join the Danish drugmaker next month and relocate to Denmark with his wife.“This opportunity comes at a pivotal moment for the company, and I am eager to get started and contribute to our mission of improving the lives of people living with chronic diseases,” he said.

He added that he sees“great potential to strengthen our global communication and public affairs efforts, reinforcing our commitment to innovation and the patients who benefit from it,” and said he was inspired by Novo Nordisk's“talented and passionate team.”

Miley most recently served as senior VP of government affairs at AbbVie and previously held roles at Abbott Laboratories and Pfizer. His experience in Washington could prove valuable as drug manufacturers face pressure from the Trump administration to curb the cost of blockbuster medications, including the GLP-1 drugs that have driven Novo Nordisk's rapid growth.

Reuters and other outlets have reported that the company is working to address heightened political attention to pricing and access in the US, its largest market.

MENAFN20102025000219011063ID1110222165